ABCL as reported
AbCellera Biologics Inc. reported $79M of revenue over the trailing twelve months, +243% on the year before. 9 reported series are charted on this page, each one as filed.
$79M
Revenue, trailing twelve months · to Q1 2026 · +243% against the twelve months before
- Net Income
- −$144M
Net Income · −14% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- −$189M
Free Cash Flow · +32% year on year · trailing twelve months to Q1 2026
- Op Margin
- −474%
Op Margin · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $79M | +243% | Q1 2026 |
| Net Income | −$144M | −14% | Q1 2026 |
| EPS | −$0.48 | −14% | Q1 2026 |
| Op Margin | −474% | n/a | Q1 2026 |
| Net Margin | −345% | n/a | Q1 2026 |
| ROE | −16% | n/a | Q1 2026 |
| ROA | −12% | n/a | Q1 2026 |
| Free Cash Flow | −$189M | +32% | Q1 2026 |
| P/E | 16.2 | n/a | Q4 2022 · 13 quarters behind |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
AbCellera Biologics Inc. (ABCL) - Revenue & ProfitRevenue & ProfitAbCellera Biologics Inc. (ABCL)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com